Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA 3rd, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team.

J Infect Dis. 2010 Mar;201(5):662-71. doi: 10.1086/650543.

2.

Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.

Halvas EK, Wiegand A, Boltz VF, Kearney M, Nissley D, Wantman M, Hammer SM, Palmer S, Vaida F, Coffin JM, Mellors JW.

J Infect Dis. 2010 Mar;201(5):672-80. doi: 10.1086/650542.

3.

Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.

Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, Günthard HF, Cavassini M.

Clin Infect Dis. 2009 Jan 15;48(2):239-47. doi: 10.1086/595703.

4.

Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.

Metzner KJ, Scherrer AU, von Wyl V, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Hirsch HH, Vernazza PL, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard HF; Swiss HIV Cohort Study.

AIDS. 2014 Sep 24;28(15):2231-9. doi: 10.1097/QAD.0000000000000397.

5.

Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.

Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, Malan E, Marais B, Stehlau R, Ledwaba J, Hammer SM, Morris L, Kuhn L.

Clin Infect Dis. 2009 Feb 15;48(4):462-72. doi: 10.1086/596486.

6.

Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.

Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen MR, Hullsiek KH, Ostergaard L, Miller MD, Kuritzkes DR.

J Infect Dis. 2013 Mar 15;207(6):893-7. doi: 10.1093/infdis/jis925. Epub 2012 Dec 21.

7.

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR.

JAMA. 2011 Apr 6;305(13):1327-35. doi: 10.1001/jama.2011.375. Review.

8.

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiek KH, Miller MD, Bangsberg DR, Kuritzkes DR.

AIDS. 2012 Jan 14;26(2):185-92. doi: 10.1097/QAD.0b013e32834e9d7d. Review.

9.

Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.

Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, Johnson M, Li JF, Heneine W, Johnson JA.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):569-73. doi: 10.1097/QAI.0b013e3181ba11e8.

PMID:
19779307
10.

Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.

Chung MH, Beck IA, Dross S, Tapia K, Kiarie JN, Richardson BA, Overbaugh J, Sakr SR, John-Stewart GC, Frenkel LM.

J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):246-53. doi: 10.1097/QAI.0000000000000312.

11.

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.

Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM.

J Infect Dis. 2008 Mar 15;197(6):867-70. doi: 10.1086/528802.

PMID:
18269317
12.

Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.

Jourdain G, Wagner TA, Ngo-Giang-Huong N, Sirirungsi W, Klinbuayaem V, Fregonese F, Nantasen I, Techapornroong M, Halue G, Nilmanat A, Wittayapraparat P, Chalermpolprapa V, Pathipvanich P, Yuthavisuthi P, Frenkel LM, Lallemant M; Program for HIV Prevention and Treatment (PHPT) Study Group.

Clin Infect Dis. 2010 May 15;50(10):1397-404. doi: 10.1086/652148.

13.

Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.

Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ; Study 934 Team.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):209-21. doi: 10.1097/QAI.0b013e3181b05f7c.

PMID:
19644384
14.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
15.

Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.

Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, Zolopa AR, Clavel F, Hance AJ.

J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):37-42.

PMID:
15608522
16.

Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V.

Pediatr Infect Dis J. 2009 Sep;28(9):826-30. doi: 10.1097/INF.0b013e3181a458f9.

PMID:
19654564
17.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study group.

PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23.

18.

Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.

Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM.

J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):547-54.

PMID:
18193496
19.

Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.

Tambuyzer L, Vingerhoets J, Azijn H, Daems B, Nijs S, de Béthune MP, Picchio G.

AIDS Res Hum Retroviruses. 2010 Nov;26(11):1197-205. doi: 10.1089/aid.2009.0302. Epub 2010 Sep 20.

PMID:
20854144
20.

Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.

Nishizawa M, Matsuda M, Hattori J, Shiino T, Matano T, Heneine W, Johnson JA, Sugiura W.

PLoS One. 2015 Sep 11;10(9):e0135941. doi: 10.1371/journal.pone.0135941. eCollection 2015.

Supplemental Content

Support Center